MabVax Therapeutics to Hold Investor Webcast and Conference Call on Thursday, October 22nd at 11:00 am EDT

SAN DIEGO, Oct. 20, 2015 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage immuno-oncology drug development company announced today its CEO, David Hansen, will host an investor webcast and conference call on Thursday, October 22, 2015 at 11:00 am EDT.  A brief Q & A session will follow the presentation.

Mr. Hansen will provide an overview of the company's differentiated approach to Immuno-Oncology as well as further outline plans to initiate two complementary Phase I clinical trials in the first quarter of 2016.  One Phase I trial will be a safety study for its fully-human antibody candidate, HuMab 5B1, as a therapeutic treatment for metastatic pancreatic cancer, and a second Phase I trial will be aimed at demonstrating the utility of ⁸⁹Zr-HuMab 5B1, the Company's radio-labeled HuMab 5B1 antibody, as a next-generation PET imaging agent for the diagnosis, staging, and management of pancreatic cancer.

The live webcast, with illustrative slides, can be accessed at http://public.viavid.com/index.php?id=116829 or at the investor relations section of the Company's web site, http://www.mabvax.com/investor-overview.php

To access the conference call, dial (855) 327-6837. 
International callers should dial (631) 891-4304.

A replay of the webcast will be available at the investor relations section of the Company's web site, http://www.mabvax.com/investor-overview.php.

About MabVax:

MabVax Therapeutics Holdings, Inc. is a clinical stage biotechnology company focused on the development of vaccine and antibody based products to address unmet medical needs in the treatment of cancer.  MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers with the Company's proprietary vaccines. MabVax also has the exclusive license to the therapeutic vaccines from Memorial Sloan Kettering Cancer Center.  MabVax has two cancer vaccines targeting recurrent sarcoma and ovarian cancer in proof of concept Phase II multi-center clinical trials, and a vaccine targeting neuroblastoma that will be ready for Phase II clinical trial later this year. Additional information about the Company is available at www.mabvax.com.

Forward Looking Statements

This press release contains "forward-looking statements" regarding matters that are not historical facts, including statements relating to the Company's development pipeline.  We have no assurance that all of the product development pipeline will be fully developed by the Company.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Words such as "anticipates," "plans," "expects," "intends," "will," "potential," "hope" and similar expressions are intended to identify forward-looking statements.  These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties.  Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its annual report on Form 10-K for the fiscal year ended December 31, 2014, as amended and supplemented from time to time and  the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov.  The parties do not undertake any obligation to update forward-looking statements contained in this press release.

Investor Contact:

Jody Cain
Senior Vice President
LHA
310-691-7100
[email protected]

Robert B. Prag, President
The Del Mar Consulting Group, Inc.
858-794-9500
[email protected]

or

Scott Wilfong, President
Alex Partners, LLC
425-242-0891
[email protected]

SOURCE MabVax Therapeutics Holdings, Inc.

Related Links

http://www.mabvax.com